BENLYSTA® speciális gyógyszerhasználati vizsgálat
2026. április 24. frissítette: GlaxoSmithKline
BENLYSTA intravénás injekció/szubkután injekció speciális gyógyszerhasználati vizsgálatához
Ennek a tanulmánynak az a célja, hogy összegyűjtse és értékelje a Benlysta intravénás injekció és a Benlysta szubkután injekció (a továbbiakban: "Benlysta") hosszú távú biztonságosságára és hatékonyságára vonatkozó információkat a napi klinikai gyakorlatban.
Az a cél, hogy ezt a kábítószer-használati vizsgálatot (DUI) minden alanynál lefolytassa mindaddig, amíg a Benlysta forgalomba hozatala után bizonyos számú alanyról össze nem gyűlnek az adatok, a Benlysta biztonságosságára és hatékonyságára vonatkozó adatokat korai szakaszban gyűjtik, és ezáltal megteszik a szükséges intézkedéseket. a Benlysta megfelelő használatához.
Körülbelül 600 alanyt vonnak be ebbe a vizsgálatba.
A megfigyelési időszak alanyonként 52 hét a Benlysta-kezelés kezdetétől számítva.
A BENLYSTA a GlaxoSmithKline (GSK) vállalatcsoport bejegyzett védjegye.
A tanulmány áttekintése
Tanulmány típusa
Megfigyelő
Beiratkozás (Tényleges)
1514
Kapcsolatok és helyek
Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.
Tanulmányi helyek
-
-
-
Hiroshima, Japán, 730-0001
- GSK Investigational Site
-
-
Részvételi kritériumok
A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.
Jogosultsági kritériumok
Tanulmányozható életkorok
- Gyermek
- Felnőtt
- Idősebb felnőtt
Egészséges önkénteseket fogad
Nem
Mintavételi módszer
Valószínűségi minta
Tanulmányi populáció
A vizsgálat minden olyan alanyra kiterjed, akiknek a Benlysta-t alkalmazzák.
Ezen túlmenően a bevezetés után kezdődő alanyok között szerepelnek azok is, akiknek a Benlysta már a szerződés megkötése előtt beadta, valamint azok, akik már megkezdték a kezelést a diagnóziskor, kórházi áthelyezés stb. miatt.
Leírás
Bevételi kritériumok:
- A vizsgálat minden olyan alanyra kiterjed, akiknek a Benlysta-t alkalmazzák. Ezen túlmenően a bevezetés után kezdődő alanyok között szerepelnek azok is, akiknek a Benlysta már a szerződés megkötése előtt beadta, valamint azok, akik már megkezdték a kezelést a diagnóziskor, kórházi áthelyezés stb. miatt.
Kizárási kritériumok:
- N/A
Tanulási terv
Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.
Hogyan készül a tanulmány?
Tervezési részletek
- Megfigyelési modellek: Csak esetre
- Időperspektívák: Leendő
Kohorszok és beavatkozások
Csoport / Kohorsz |
Beavatkozás / kezelés |
|---|---|
|
Benlysta intravenous (IV)
Participants with systemic lupus erythematosus (SLE) received Benlysta via intravenous (IV) administration for 52 weeks as a part of their treatment regimen.
|
Benlysta was administered
|
|
Benlysta subcutaneous (SC)
Participants with SLE received Benlysta via subcutaneous (SC) administration for 52 weeks as a part of their treatment regimen.
|
Benlysta was administered
|
|
Benlysta switched from IV to SC or SC to IV
Participants with SLE received Benlysta for 52 weeks as a part of their treatment regimen, where initial administration was IV but switched to SC, or where the initial administration was SC but switched to IV during the study.
|
Benlysta was administered
|
|
Benlysta IV or SC (Initial route of administration unknown)
Participants with SLE received Benlysta via IV or SC administration for 52 weeks as a part of their treatment regimen.
It was unknown whether the initial administration was IV or SC for participants in this arm.
|
Benlysta was administered
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Number of Participants With Adverse Drug Reactions (ADRs)
Időkeret: From the start of the study intervention (Day 1) up to maximum of 3 years
|
ADR is defined as a response to a drug which is noxious and unintended, and which occurred at doses normally used in human for the prophylaxis, diagnosis, or therapy of disease, or for the modifications of physiological function.
|
From the start of the study intervention (Day 1) up to maximum of 3 years
|
|
Number of Participants With Serious ADR of Events Defined as a Priority Study Matter
Időkeret: From the start of the study intervention (Day 1) up to maximum of 3 years
|
ADR is defined as a response to a drug which is noxious and unintended, and which occurred at doses normally used in human for the prophylaxis, diagnosis, or therapy of disease, or for the modifications of physiological function.
Following serious ADRs were considered as priority study matter: 1. Serious hypersensitivity, 2. Serious infections (including tuberculosis, pneumonia, pneumocystis pneumonia, sepsis, and opportunistic infection), 3. Reactivation of hepatitis B virus, 4. Progressive multifocal leukoencephalopathy, 5. Interstitial pneumonitis, 6. Malignant tumor, 7. Depression and events related to suicide/self-injury.
|
From the start of the study intervention (Day 1) up to maximum of 3 years
|
|
Change From Baseline in Safety of Estrogens in Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA SLEDAI) Score at Week 24
Időkeret: Baseline (Day 0) and Week 24
|
The SELENA-SLEDAI score is a cumulative and weighted index for assessing systemic lupus erythematosus (SLE) disease activity in participants with SLE.
It consists of 24 disease descriptors related to signs and symptoms, laboratory tests, and physician's assessment across 9 organ systems.
Each descriptor is assigned a weighted score (8 descriptors with a weight of 8 each, 6 descriptors with a weight of 4 each, 7 descriptors with a weight of 2 each, and 3 descriptors with a weight of 1 each) which is added up if the descriptor is observed during a visit or within the preceding 10 days.
The total score ranges from 0 (no disease activity) to 105 (all 24 descriptors present simultaneously).
A higher score indicates a more significant degree of disease activity.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 24
|
|
Change From Baseline in SELENA SLEDAI Score at Week 52
Időkeret: Baseline (Day 0) and Week 52
|
The SELENA-SLEDAI score is a cumulative and weighted index for assessing systemic lupus erythematosus (SLE) disease activity in participants with SLE.
It consists of 24 disease descriptors related to signs and symptoms, laboratory tests, and physician's assessment across 9 organ systems.
Each descriptor is assigned a weighted score (8 descriptors with a weight of 8 each, 6 descriptors with a weight of 4 each, 7 descriptors with a weight of 2 each, and 3 descriptors with a weight of 1 each) which is added up if the descriptor is observed during a visit or within the preceding 10 days.
The total score ranges from 0 (no disease activity) to 105 (all 24 descriptors present simultaneously).
A higher score indicates a more significant degree of disease activity.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 52
|
|
Change From Baseline in Lupus Impact Tracker Score at Week 24
Időkeret: Baseline (Day 0) and Week 24
|
Lupus impact tracker is 10-item patient reported outcome tool to measure impact of systemic lupus erythematosus or its treatment on participants' daily lives.
Each answer for items is marked from 0 (none of the time) to 4 (all of the time) points.
Lower the lupus impact score, less impact lupus is having on life of participant.
Total score was derived by adding up scores of all 10 items.
Total score ranges from 0 (less impact on daily life) to 40 (greater impact on daily life).
Higher score indicates greater impact of lupus on quality of life.
|
Baseline (Day 0) and Week 24
|
|
Change From Baseline in Lupus Impact Tracker Score at Week 52
Időkeret: Baseline (Day 0) and Week 52
|
Lupus impact tracker is 10-item patient reported outcome tool to measure impact of systemic lupus erythematosus or its treatment on participants' daily lives.
Each answer for items is marked from 0 (none of the time) to 4 (all of the time) points.
Lower the lupus impact score, less impact lupus is having on life of participant.
Total score was derived by adding up scores of all 10 items.
Total score ranges from 0 (less impact on daily life) to 40 (greater impact on daily life).
Higher score indicates greater impact of lupus on quality of life.
|
Baseline (Day 0) and Week 52
|
|
Change From Baseline in Physician's Global Assessment (PGA) Score at Week 24
Időkeret: Baseline (Day 0) and Week 24
|
The PGA is used to assess the participant's current disease activity by investigator.
It was collected on a 10 centimeter (cm) visual analogue scale (VAS).
The score ranges from 0 (no activity) to 3 (severe activity).
Lower score means no disease activity, higher score means severe disease activity.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 24
|
|
Change From Baseline in PGA Score at Week 52
Időkeret: Baseline (Day 0) and Week 52
|
The PGA is used to assess the participant's current disease activity by investigator.
It was collected on a 10 centimeter (cm) visual analogue scale (VAS).
The score ranges from 0 (no activity) to 3 (severe activity).
Lower score means no disease activity, higher score means severe disease activity.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 52
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 4
Időkeret: Baseline (Day 0) and Week 4
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 4
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 8
Időkeret: Baseline (Day 0) and Week 8
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 8
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 12
Időkeret: Baseline (Day 0) and Week 12
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 12
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 16
Időkeret: Baseline (Day 0) and Week 16
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 16
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 20
Időkeret: Baseline (Day 0) and Week 20
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 20
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 24
Időkeret: Baseline (Day 0) and Week 24
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 24
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 28
Időkeret: Baseline (Day 0) and Week 28
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 28
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 32
Időkeret: Baseline (Day 0) and Week 32
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 32
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 36
Időkeret: Baseline (Day 0) and Week 36
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 36
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 40
Időkeret: Baseline (Day 0) and Week 40
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 40
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 44
Időkeret: Baseline (Day 0) and Week 44
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 44
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 48
Időkeret: Baseline (Day 0) and Week 48
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 48
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 52
Időkeret: Baseline (Day 0) and Week 52
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 52
|
|
Number of Participants Who Achieved Lupus Low Disease Activity State (LLDAS) Response Criteria at Week 24
Időkeret: At Week 24
|
LLDAS was defined as a state which, if sustained, was associated with a low likelihood of adverse outcome, considering disease activity and medication safety.
The LLDAS response criteria were: (1) Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) less than equal to (<=)4 and no major active organ involvement (renal, central nervous system, cardiopulmonary, vasculitis, and pyrexia) and without hemolytic anemia or active gastrointestinal lesions; (2) no new signs or symptoms as compared to the last SELENA-SLEDAI assessment; (3) PGA score <=1 (33 millimeter); (4) corticosteroid dose <=7.5 milligram (mg)/day at time of assessment; and (5) use of the same immunosuppressant as compared with prior medication.
No unapproved immunosuppressant drugs like rituximab, anifrolumab, ustekinumab, or baricitinib were used as concomitant medications.
|
At Week 24
|
|
Number of Participants Who Achieved LLDAS Response Criteria at Week 52
Időkeret: At Week 52
|
LLDAS was defined as a state which, if sustained, was associated with a low likelihood of adverse outcome, considering disease activity and medication safety.
The LLDAS response criteria were: (1) Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) less than equal to (<=)4 and no major active organ involvement (renal, central nervous system, cardiopulmonary, vasculitis, and pyrexia) and without hemolytic anemia or active gastrointestinal lesions; (2) no new signs or symptoms as compared to the last SELENA-SLEDAI assessment; (3) PGA score <=1 (33 millimeter); (4) corticosteroid dose <=7.5 milligram (mg)/day at time of assessment; and (5) use of the same immunosuppressant as compared with prior medication.
No unapproved immunosuppressant drugs like rituximab, anifrolumab, ustekinumab, or baricitinib were used as concomitant medications.
|
At Week 52
|
|
Change From Baseline in Blood Levels of Anti-double-stranded Deoxyribonucleic Acid (Anti-dsDNA) Antibody at Week 24
Időkeret: Baseline (Day 0) and Week 24
|
Blood samples were collected for anti-dsDNA antibody biomarker analysis.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 24
|
|
Change From Baseline in Blood Levels of Anti-dsDNA Antibody at Week 52
Időkeret: Baseline (Day 0) and Week 52
|
Blood samples were collected for anti-dsDNA antibody biomarker analysis.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 52
|
|
Change From Baseline in Blood Levels of Complement Component-3 (C3) and Complement Component-4 (C4) at Week 24
Időkeret: Baseline (Day 0) and Week 24
|
Blood samples were collected from participants to assess C3 and C4 levels.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 24
|
|
Change From Baseline in Blood Levels of Complement Component-3 (C3) and Complement Component-4 (C4) at Week 52
Időkeret: Baseline (Day 0) and Week 52
|
Blood samples were collected from participants to assess C3 and C4 levels.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 52
|
|
Change From Baseline in Blood Levels of Complement Hemolytic Activity at 50% (CH50) at Week 24
Időkeret: Baseline (Day 0) and Week 24
|
Blood samples were collected from participants to assess CH50 concentrations.
CH50 is a blood test that measures the overall activity of the complement system, a group of proteins crucial for the immune system's function.
Low CH50 levels can be associated with certain infections.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 24
|
|
Change From Baseline in Blood Levels of Complement Hemolytic Activity at 50% (CH50) at Week 52
Időkeret: Baseline (Day 0) and Week 52
|
Blood samples were collected from participants to assess CH50 concentrations.
CH50 is a blood test that measures the overall activity of the complement system, a group of proteins crucial for the immune system's function.
Low CH50 levels can be associated with certain infections.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 52
|
|
Change From Baseline in Urine Protein/Creatinine Ratio at Week 24
Időkeret: Baseline (Day 0) and Week 24
|
Urine samples were collected from participants to assess Urine Protein/Creatinine Ratio.
It is a test that estimates how much protein is being excreted in urine, normalized to creatinine.
It's commonly used to assess kidney function and detect proteinuria.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 24
|
|
Change From Baseline in Urine Protein/Creatinine Ratio at Week 52
Időkeret: Baseline (Day 0) and Week 52
|
Urine samples were collected from participants to assess Urine Protein/Creatinine Ratio.
It is a test that estimates how much protein is being excreted in urine, normalized to creatinine.
It's commonly used to assess kidney function and detect proteinuria.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 52
|
Együttműködők és nyomozók
Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.
Szponzor
Nyomozók
- Tanulmányi igazgató: GSK Clinical Trials, GlaxoSmithKline
Tanulmányi rekorddátumok
Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
2018. január 15.
Elsődleges befejezés (Tényleges)
2025. július 31.
A tanulmány befejezése (Tényleges)
2025. július 31.
Tanulmányi regisztráció dátumai
Először benyújtva
2017. december 6.
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
2017. december 6.
Első közzététel (Tényleges)
2017. december 12.
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
2026. május 18.
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
2026. április 24.
Utolsó ellenőrzés
2026. április 1.
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- 207735
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
NEM
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Nem
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Nem
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .